← back to search

Tom van der Poll

Biology of Infection · NL
Area of research
Epidemiology · Immunology
Research interest
Research interests include Immune Response and Inflammation, Sepsis Diagnosis and Treatment, Blood Coagulation and Thrombosis Mechanisms, and Pneumonia and Respiratory Infections.
h-index
138
citations
117,391
works
1,224
NIH funding
primary concept
email

Recent publications

Biological drivers of the host response in sepsis.
2026cited by 3position: contributordoi
Reply to Feng et al.: Potential pitfalls in proteomic risk assessment for community-acquired pneumonia.
2026cited by 0position: contributordoi
Single-cell proteome profiling reveals distinct immunological patterns in the lungs of patients with severe acute respiratory failure
2026cited by 0position: contributordoi
Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies
The Lancet Respiratory Medicine 2025cited by 30position: contributordoi
Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies
The Lancet Respiratory Medicine 2025cited by 29position: middledoi
A consensus immune dysregulation framework for sepsis and critical illnesses
Nature Medicine 2025cited by 23position: middledoi
A consensus blood transcriptomic framework for sepsis
Nature Medicine 2025cited by 18position: lastdoi
The immunology of sepsis: translating new insights into clinical practice
Nature Reviews Nephrology 2025cited by 14position: middledoi
Effect of the gut microbiota-derived tryptophan metabolite indole-3-acetic acid in pneumonia
Nature Communications 2025cited by 11position: middledoi
A consensus blood transcriptomic framework for sepsis.
2025cited by 7position: contributordoi
A consensus immune dysregulation framework for sepsis and critical illnesses.
2025cited by 7position: contributordoi
Pathogen-specific host response in critically ill patients with blood stream infections: a nested case–control study
eBioMedicine 2025cited by 6position: contributordoi
Effect of the gut microbiota-derived tryptophan metabolite indole-3-acetic acid in pneumonia.
2025cited by 5position: contributordoi
Unraveling Sepsis Epidemiology in a Low- and Middle-Income Intensive Care Setting Reveals the Alarming Burden of Tropical Infections and Antimicrobial Resistance: A Prospective Observational Study (MARS-India).
2025cited by 5position: contributordoi
Author Correction: A consensus immune dysregulation framework for sepsis and critical illnesses
Nature Medicine 2025cited by 4position: middledoi
Author Correction: A consensus immune dysregulation framework for sepsis and critical illnesses.
2025cited by 3position: contributordoi
Uncovering metabolic pathways in human alveolar macrophages in response to lipopolysaccharide.
2025cited by 1position: contributordoi
A bioenergetic basis for multiorgan dysfunction in sepsis
2025cited by 0position: contributordoi
Flagellin-mediated TLR5 activation enhances innate immune responses in healthy and diseased human airway epithelium
2025cited by 0position: contributordoi
The pathophysiology of sepsis and precision-medicine-based immunotherapy
Nature Immunology 2024cited by 300position: middledoi
The pathophysiology of sepsis and precision-medicine-based immunotherapy
Nature Immunology 2024cited by 292position: contributordoi
From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations for Developing Precision Medicine in the ICU
American Journal of Respiratory and Critical Care Medicine 2024cited by 89position: middledoi
Temporal Transitions of the Hyperinflammatory and Hypoinflammatory Phenotypes in Critical Illness
American Journal of Respiratory and Critical Care Medicine 2024cited by 38position: middledoi
The Plasma Lipidomic Landscape in Patients with Sepsis due to Community-acquired Pneumonia
American Journal of Respiratory and Critical Care Medicine 2024cited by 36position: lastdoi
The Plasma Lipidomic Landscape in Patients with Sepsis due to Community-acquired Pneumonia.
2024cited by 30position: contributordoi
Validation of SeptiCyte RAPID to Discriminate Sepsis from Non-Infectious Systemic Inflammation
Journal of Clinical Medicine 2024cited by 26position: middledoi
Monocyte state 1 (MS1) cells in critically ill patients with sepsis or non-infectious conditions: association with disease course and host response
Critical Care 2024cited by 17position: lastdoi
The alveolar fibroproliferative response in moderate to severe COVID-19-related acute respiratory distress syndrome and 1-yr follow-up.
2024cited by 7position: contributordoi
Effect of mesenchymal stem cells on the host response in severe community-acquired pneumonia.
2024cited by 5position: contributordoi
Persistent alveolar inflammatory response in critically ill patients with COVID-19 is associated with mortality.
2023cited by 30position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 32 papers (2019–2026)Olaf L. Cremer · Utrecht University13 papers (2015–2025)Marc J. M. Bonten · Perth Children's Hospital8 papers (2015–2024)Tom D. Y. Reijnders · Amsterdam UMC Location University of Amsterdam8 papers (2021–2024)Marcus J. Schultz · Nuffield Health8 papers (2012–2024)W. Joost Wiersinga · Centrum Wiskunde & Informatica8 papers (2012–2025)Hessel Peters Sengers · Center for Translational Molecular Medicine7 papers (2022–2026) · 6 papers (2016–2025)Mihai G. Netea · Eindhoven University of Technology6 papers (2017–2025)Timothy E. Sweeney · Infinera (United States)5 papers (2024–2025) · 5 papers (2015–2025)Carolyn S. Calfee · Precision Research (United States)5 papers (2017–2025)Peter M. C. Klein Klouwenberg · Utrecht University5 papers (2015–2019)Alexander P. J. Vlaar · Amsterdam University Medical Centers5 papers (2012–2025)David S. Y. Ong · Utrecht University5 papers (2015–2018)Brendon P. Scicluna · Mater Dei Hospital5 papers (2021–2025)Pierre‐François Laterre · UCLouvain4 papers (2020–2025)Lieuwe D. J. Bos · Amsterdam Neuroscience4 papers (2017–2025)Richard A. Flavell · University of California, San Francisco4 papers (2012–2013)Joris J. T. H. Roelofs · Institut Pasteur4 papers (2012–2025)